Hypercholesterolemia is one of the main risk factors for the development of atherosclerosis. Among the various lipoprotein classes, however, high density lipoproteins (HDL) are inversely associated with the incidence of atherosclerosis, since they are able to exert a series of atheroprotective functions. The central role of HDL within the reverse cholesterol transport, their antioxidant and anti-inflammatory properties and their ability to preserve endothelial homeostasis are likely responsible for HDL-mediated atheroprotection. However, drugs that effectively raise HDL-C failed to result in a decreased incidence of cardiovascular event, suggesting that plasma levels of HDL-C and HDL function are not always related. Several evidences are showing that different pathologic conditions, especially those associated with an inflammatory response, can cause dramatic alterations of HDL protein and lipid cargo resulting in HDL dysfunction. Established and investigational drugs designed to affect lipid metabolism and to increase HDL-C are only partly effective in correcting HDL dysfunction.
Dysfunctional HDL as a therapeutic target for atherosclerosis prevention / A. Ossoli, C. Pavanello, E. Giorgio, L. Calabresi, M. Gomaraschi. - In: CURRENT MEDICINAL CHEMISTRY. - ISSN 0929-8673. - 26:9(2019 Mar), pp. 1610-1630.
|Titolo:||Dysfunctional HDL as a therapeutic target for atherosclerosis prevention|
OSSOLI, ALICE FEDERICA (Primo)
PAVANELLO, CHIARA (Secondo)
CALABRESI, LAURA (Penultimo)
GOMARASCHI, MONICA (Ultimo) (Corresponding)
|Parole Chiave:||Atherosclerosis; Autoimmune Disorders; Chronic Kidney Disease; Coronary Heart Disease; Diabetes; High Density Lipoproteins; Inflammation.|
|Settore Scientifico Disciplinare:||Settore BIO/14 - Farmacologia|
|Data di pubblicazione:||mar-2019|
|Data ahead of print / Data di stampa:||15-mar-2018|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.2174/0929867325666180316115726|
|Appare nelle tipologie:||01 - Articolo su periodico|